William McElveen, MD
Neurology · Columbia, SCNPI 1528121449
Payments from drug & device makers
Across 293 payments — averaging $12,698 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$1.5M
- Eli Lilly$750K
- Genentech, Inc.$541K
- Biogen$405K
- Novartis$308K
- Grifols Biologicals LLC$65K
- plus $134K from 5 others
Across 4 payments — averaging $1206.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$5K
What the payments were for
- Travel & lodging$1,14483%
- Food & beverage$18814%
- Education$433%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 146 | $1,516,875 |
| Eli Lilly | 16 | $749,629 |
| Genentech, Inc. | 49 | $540,833 |
| Biogen | 7 | $405,337 |
| Novartis | 9 | $308,144 |
| Grifols Biologicals LLC | 2 | $65,336 |
| Roche Products Limited | 10 | $44,988 |
| Osmotica Pharmaceutical Corp. | 9 | $30,010 |
| Novo Nordisk AS | 34 | $26,737 |
| Amgen | 8 | $17,522 |
| SK Life Science, Inc. | 3 | $15,098 |
How this compares
$3,720,509 in reported general payments places this provider in the 95th percentile of 270 neurology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Memantine Hcl | 150 | $5,524 |
| Donepezil Hcl | 256 | $2,563 |
| Rivastigmine | 13 | $1,764 |
| Galantamine ErGalantamine Hbr | 17 | $1,440 |
| Galantamine Hbr | 15 | $1,140 |
| Quetiapine Fumarate | 29 | $533 |
| Bupropion XlBupropion Hcl | 12 | $394 |
| Escitalopram Oxalate | 23 | $329 |
| Citalopram HbrCitalopram Hydrobromide | 38 | $176 |
| Mirtazapine | 18 | $109 |
Paid to pharmacies, not to this prescriber.
Other neurology in Columbia
- Eleanya Ogburu-OgbonnayaColumbia$137K
- Joseph FerraraColumbia$99K
- David HammettColumbia$86K
- Davit MrelashviliColumbia$70K
- Pradeep BolluColumbia$55K
- Miroslav CuturicColumbia$27K
- Mary HughesGreenville$6.3M
- Robert CarlileSummerville$2.3M
- Andrew KeeganCharleston$2.2M
- Paul MazzeoPort Royal$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.